Interim report 2026
Filed with HKEX · Stock code 1358 · · 56 pages · English
We are a leading medical device company with the focus on fast-growing and high-margin segments of China’s medical device industry. We have a leading market position in our current business segments of infusion sets, blood purification products and regenerative medical biomaterials, with strong research and development capabilities and well-established distribution networks. CONTENTS 02Definitions
Earlier from PW Medtech
- Notice of the 2021 annual general meeting
- Discloseable transaction - loan transaction
- Voluntary announcement - (1) extension of exclusivity period in relation to the acquisition of cbpo shares and (2) update of consortium members
- Extension of long stop date in relation to the disposal of cbpo shares
- Poll results of the extraordinary general meeting held on November 7, 2019
Later from PW Medtech
- Notification Letter and Reply Form to Registered Shareholders
- Notification Letter and Request Form to Non-Registered Shareholders
- Inside information - the bankruptcy liquidation proceedings and asset realisation plan of a subsidiary
- Next Day Disclosure Return
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Follow PW Medtech into a list and get an email when it puts out news.
Follow PW Medtech